Distinct transcriptional programs control cross-priming in classical and monocyte-derived dendritic cells
Cell reports, 2016•cell.com
Both classical DCs (cDCs) and monocyte-derived DCs (Mo-DCs) are capable of cross-
priming CD8+ T cells in response to cell-associated antigens. We found that Ly-6C hi
TREML4− monocytes can differentiate into Zbtb46+ Mo-DCs in response to granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) but that Ly-6C hi
TREML4+ monocytes were committed to differentiate into Ly-6C lo TREML4+ monocytes.
Differentiation of Zbtb46+ Mo-DCs capable of efficient cross-priming required both GM-CSF …
priming CD8+ T cells in response to cell-associated antigens. We found that Ly-6C hi
TREML4− monocytes can differentiate into Zbtb46+ Mo-DCs in response to granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) but that Ly-6C hi
TREML4+ monocytes were committed to differentiate into Ly-6C lo TREML4+ monocytes.
Differentiation of Zbtb46+ Mo-DCs capable of efficient cross-priming required both GM-CSF …
Summary
Both classical DCs (cDCs) and monocyte-derived DCs (Mo-DCs) are capable of cross-priming CD8+ T cells in response to cell-associated antigens. We found that Ly-6ChiTREML4− monocytes can differentiate into Zbtb46+ Mo-DCs in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) but that Ly-6ChiTREML4+ monocytes were committed to differentiate into Ly-6CloTREML4+ monocytes. Differentiation of Zbtb46+ Mo-DCs capable of efficient cross-priming required both GM-CSF and IL-4 and was accompanied by the induction of Batf3 and Irf4. However, monocytes require IRF4, but not BATF3, to differentiate into Zbtb46+ Mo-DCs capable of cross-priming CD8+ T cells. Instead, Irf4−/− monocytes differentiate into macrophages in response to GM-CSF and IL-4. Thus, cDCs and Mo-DCs require distinct transcriptional programs of differentiation in acquiring the capacity to prime CD8+ T cells. These differences may be of consideration in the use of therapeutic DC vaccines based on Mo-DCs.
cell.com